PBCAR 19B
Alternative Names: PBCAR-19BLatest Information Update: 11 Jan 2024
At a glance
- Originator Baxalta; Precision Biosciences
- Developer Precision Biosciences
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma
Most Recent Events
- 11 Jan 2024 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV)
- 30 Sep 2023 Precision Biosciences completes a phase I trial in Non-Hodgkin Lymphoma(Second-line therapy or greater) in USA (IV-infusion) (NCT04649112)
- 01 Jun 2023 PBCAR 19B is available for licensing as of 30 May 2023. https://precisionbiosciences.com/partnering/